Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A bodybuilder discusses homebrewing Minoxidil and RU58841 using propylene glycol or MCT. They inquire about the feasibility and potential risks of these methods.

A 30-year-old male is experiencing some hair regrowth after 77 days using oral finasteride, topical minoxidil 5%, and a 0.5mm derma roller twice a week. Users note small hairs filling previously smooth spots, but it's too early to determine full regrowth potential.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

A 35-year-old man, balding since 18, has seen growth of small, almost white hairs all over his scalp after 1.5 months on oral finasteride and minoxidil. Users suggest sticking with the treatment for a year, adding microneedling, and potentially trying RU58841 or dutasteride.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

User reports significant hair growth after 3 months using topical minoxidil 5%, oral finasteride 1mg, a derma roller, and biotin tablets. Other users encourage continuation due to impressive results.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

A user shared their 5-month progress using Finasteride (1mg daily) and 3 months on Oral Minoxidil (5mg daily) for hair regrowth, reporting significant improvement and no side effects. They experienced initial shedding with Minoxidil but saw substantial regrowth, encouraging others to try these treatments.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

The user discusses their hair regrowth progress over almost three months using a dermaroller, Minoxidil foam, finasteride pills, and biotin gummies. They share before and after pictures to show the improvement.

A user shared their 75-day progress using oral minoxidil, finasteride, ketoconazole shampoo, and dermastamping for retrograde alopecia, reporting significant improvement and increased body hair without side effects. They also discussed quitting smoking and the potential correlation between early beard growth and male pattern baldness.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A user shared their 3-month progress using a combined finasteride and minoxidil pill for hair loss, noting early signs of regrowth. They also use biotin shampoo/conditioner, take Vyvanse and Propranolol, and bleach/dye their hair every 3 weeks.

The user experienced improved hair density and thickness after using finasteride and dermarolling for 2.5 years but noticed hair loss when doing anaerobic exercise. They increased their finasteride dose and continued dermarolling but are considering not starting minoxidil due to its perceived hassle and uncertain long-term benefits.

A 25-year-old is using a nightly routine of topical finasteride 0.3% and minoxidil 6%, along with a derma roller and Nizoral shampoo, to address crown hair loss. The user reports no side effects and noticeable improvement over 2.5 months.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

The user is on Finasteride for hair loss, taking 0.5mg daily, and plans to reduce the dose to 0.25mg while making lifestyle changes to lower prolactin, SHGB, and cortisol. They will retest in 90 days to assess progress and are open to advice.

A user's 5-month progress with Finasteride 1mg for hair loss, which is showing promising results; other users have suggested adding additional treatments such as Minoxidil and Derma Rolling to further boost regrowth.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

User wants to make homemade topical finasteride to minimize side effects and asks about using glycerin, stirring time, storage, and alternative solvents. Another user's comment is unclear.